CA2261989C - Recombinant pox virus for immunization against tumor-associated antigens - Google Patents
Recombinant pox virus for immunization against tumor-associated antigens Download PDFInfo
- Publication number
- CA2261989C CA2261989C CA002261989A CA2261989A CA2261989C CA 2261989 C CA2261989 C CA 2261989C CA 002261989 A CA002261989 A CA 002261989A CA 2261989 A CA2261989 A CA 2261989A CA 2261989 C CA2261989 C CA 2261989C
- Authority
- CA
- Canada
- Prior art keywords
- recombinant
- virus
- pox virus
- gene
- cea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 107
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 50
- 239000000427 antigen Substances 0.000 title claims abstract description 40
- 102000036639 antigens Human genes 0.000 title claims abstract description 40
- 108091007433 antigens Proteins 0.000 title claims abstract description 40
- 230000003053 immunization Effects 0.000 title description 8
- 238000002649 immunization Methods 0.000 title description 8
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 19
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 16
- 229940032310 PROSTVAC vaccine Drugs 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 5
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 4
- 102100038358 Prostate-specific antigen Human genes 0.000 claims 3
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 claims 2
- 230000028993 immune response Effects 0.000 abstract description 8
- 230000000763 evoking effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 61
- 239000013612 plasmid Substances 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 28
- 108020004414 DNA Proteins 0.000 description 27
- 206010046865 Vaccinia virus infection Diseases 0.000 description 25
- 208000007089 vaccinia Diseases 0.000 description 25
- 239000013598 vector Substances 0.000 description 22
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 14
- 239000012634 fragment Substances 0.000 description 14
- 230000003612 virological effect Effects 0.000 description 14
- 201000011510 cancer Diseases 0.000 description 13
- 229960005486 vaccine Drugs 0.000 description 13
- 241000700618 Vaccinia virus Species 0.000 description 12
- 238000010276 construction Methods 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 10
- 238000003780 insertion Methods 0.000 description 10
- 230000037431 insertion Effects 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 230000006798 recombination Effects 0.000 description 10
- 238000005215 recombination Methods 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- 101150066555 lacZ gene Proteins 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 108020004440 Thymidine kinase Proteins 0.000 description 7
- 101150045267 CEA gene Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 108010010995 MART-1 Antigen Proteins 0.000 description 6
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 6
- 102000006601 Thymidine Kinase Human genes 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 239000013603 viral vector Substances 0.000 description 6
- 102000003886 Glycoproteins Human genes 0.000 description 5
- 108090000288 Glycoproteins Proteins 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000006801 homologous recombination Effects 0.000 description 5
- 238000002744 homologous recombination Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000013600 plasmid vector Substances 0.000 description 5
- 230000002103 transcriptional effect Effects 0.000 description 5
- 241000700663 Avipoxvirus Species 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 208000000666 Fowlpox Diseases 0.000 description 4
- 241000700662 Fowlpox virus Species 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 241000700629 Orthopoxvirus Species 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 239000002955 immunomodulating agent Substances 0.000 description 4
- 229940121354 immunomodulator Drugs 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- LINMATFDVHBYOS-MBJXGIAVSA-N (2s,3r,4s,5r,6r)-2-[(5-bromo-1h-indol-3-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C=C12 LINMATFDVHBYOS-MBJXGIAVSA-N 0.000 description 3
- 241000271566 Aves Species 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 108010008038 Synthetic Vaccines Proteins 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 241000700647 Variola virus Species 0.000 description 3
- 108020005202 Viral DNA Proteins 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 239000003593 chromogenic compound Substances 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 229940124551 recombinant vaccine Drugs 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 241000700664 Capripoxvirus Species 0.000 description 2
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 230000006023 anti-tumor response Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003837 chick embryo Anatomy 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- -1 e.g. Proteins 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000001024 immunotherapeutic effect Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003156 radioimmunoprecipitation Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229940083538 smallpox vaccine Drugs 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 208000006586 Ectromelia Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 241000700563 Leporipoxvirus Species 0.000 description 1
- 206010024503 Limb reduction defect Diseases 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000700627 Monkeypox virus Species 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000700625 Poxviridae Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700564 Rabbit fibroma virus Species 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000700638 Raccoonpox virus Species 0.000 description 1
- 231100000645 Reed–Muench method Toxicity 0.000 description 1
- 241000287219 Serinus canaria Species 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000700568 Suipoxvirus Species 0.000 description 1
- 241000700565 Swinepox virus Species 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 101150003725 TK gene Proteins 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 108010059722 Viral Fusion Proteins Proteins 0.000 description 1
- 241001536558 Yaba monkey tumor virus Species 0.000 description 1
- DVKFVGVMPLXLKC-PUGXJXRHSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dihydrogen phosphate Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)[C@@]1(OP(O)(O)=O)[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DVKFVGVMPLXLKC-PUGXJXRHSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002494 anti-cea effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000011398 antitumor immunotherapy Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 102000007579 human kallikrein-related peptidase 3 Human genes 0.000 description 1
- 108010071652 human kallikrein-related peptidase 3 Proteins 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000001589 lymphoproliferative effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000005871 monkeypox Diseases 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000012809 post-inoculation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 210000004908 prostatic fluid Anatomy 0.000 description 1
- 238000011536 re-plating Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000012340 reverse transcriptase PCR Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68628096A | 1996-07-25 | 1996-07-25 | |
| US08/686,280 | 1996-07-25 | ||
| PCT/US1997/012203 WO1998004727A1 (en) | 1996-07-25 | 1997-07-15 | Recombinant pox virus for immunization against tumor-associated antigens |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2261989A1 CA2261989A1 (en) | 1998-02-05 |
| CA2261989C true CA2261989C (en) | 2008-09-30 |
Family
ID=24755674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002261989A Expired - Fee Related CA2261989C (en) | 1996-07-25 | 1997-07-15 | Recombinant pox virus for immunization against tumor-associated antigens |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7410644B2 (index.php) |
| EP (2) | EP2112225A1 (index.php) |
| JP (2) | JP4475683B2 (index.php) |
| AU (1) | AU731860B2 (index.php) |
| CA (1) | CA2261989C (index.php) |
| WO (1) | WO1998004727A1 (index.php) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2168952A1 (en) * | 1993-08-11 | 1995-02-16 | Lynn E. Spitler | Prostatic cancer vaccine |
| US20010036928A1 (en) * | 1996-04-22 | 2001-11-01 | Chamberlain Ronald S. | Heterologous boosting immunizations |
| US6969609B1 (en) | 1998-12-09 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Serivces | Recombinant vector expressing multiple costimulatory molecules and uses thereof |
| US7148035B1 (en) | 1998-11-18 | 2006-12-12 | Oxford Biomedica (Uk) Limited | Polypeptide |
| AU766954B2 (en) * | 1998-11-18 | 2003-10-30 | Oxford Biomedica (Uk) Limited | Polypeptide |
| EP1865065A1 (en) * | 1998-12-09 | 2007-12-12 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | A recombinant vector expressing multiple costimulatory molecules and uses thereof |
| CA2354024C (en) * | 1998-12-09 | 2009-12-22 | Jeffrey Schlom | A recombinant vector expressing multiple costimulatory molecules and uses thereof |
| EP1496939B1 (en) * | 2002-04-09 | 2007-08-15 | Sanofi Pasteur Limited | Modified cea nucleic acid and expression vectors |
| US20070196346A1 (en) * | 2003-08-21 | 2007-08-23 | Brown Michael P | Poxvirus Vector Encoding Prostate Specific Antigens For Treatment Of Prostate Cancer |
| US8562970B2 (en) * | 2003-10-08 | 2013-10-22 | Sanofi Pasteur Limited | Modified CEA/B7 vector |
| WO2005046622A2 (en) | 2003-11-12 | 2005-05-26 | Therion Biologics Corporation | Custom vectors for treating and preventing pancreatic cancer |
| JP4995575B2 (ja) | 2003-11-12 | 2012-08-08 | アメリカ合衆国 | 乳癌を処置および予防するためのシステム |
| US20110287089A1 (en) | 2009-01-13 | 2011-11-24 | Karola Rittner | Use of a saccharomyces cerevisiae mitochondrial nucleic acids fraction for immune stimulation |
| MX2011007386A (es) | 2009-01-20 | 2011-08-03 | Transgene Sa | Icam-1 soluble como un biomarcador para la prediccion de una respuesta terapeutica. |
| NZ595290A (en) | 2009-03-24 | 2012-09-28 | Transgene Sa | Biomarker for monitoring patients |
| US20120058493A1 (en) | 2009-04-17 | 2012-03-08 | Bruce Acres | Biomarker for monitoring patients |
| CA2767458A1 (en) | 2009-07-10 | 2011-01-13 | Bruce Acres | Biomarker for selecting patients and related methods |
| EP2601529B8 (en) | 2010-08-06 | 2017-01-25 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Biomarkers for predicting response to a cancer vaccine |
| US9725494B2 (en) * | 2013-05-17 | 2017-08-08 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Soluble CD27 (sCD27) and the use thereof |
| JP6535337B2 (ja) * | 2013-11-05 | 2019-06-26 | バヴァリアン・ノルディック・アクティーゼルスカブ | 腫瘍抗原を発現するポックスウイルスならびに免疫チェックポイント阻害剤のアンタゴニスト及び／またはアゴニストにより癌を治療するための組み合わせ療法 |
| IL248511B (en) | 2014-05-13 | 2022-07-01 | Bavarian Nordic As | Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against tim-3 |
| KR102504758B1 (ko) | 2014-07-16 | 2023-02-28 | 트랜스진 | 종양 세포 붕괴성 바이러스와 면역 체크포인트 조절제의 배합물 |
| ES3011733T3 (en) | 2015-02-13 | 2025-04-08 | Transgene | Immunotherapeutic vaccine and antibody combination therapy |
| MX389312B (es) | 2015-07-31 | 2025-03-20 | Bavarian Nordic As | Promotores para mejorar la expresion en poxvirus. |
| EP3400009A2 (en) | 2016-01-05 | 2018-11-14 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Combination of histone deacetylase inhibitor and immunotherapy |
| ES2924741T3 (es) | 2016-01-28 | 2022-10-10 | Inst Nat Sante Rech Med | Métodos para incrementar la potencia de los inhibidores del punto de control inmunitario |
| WO2017136342A1 (en) | 2016-02-02 | 2017-08-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells |
| CA3023022A1 (en) | 2016-05-04 | 2017-11-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
| EP3518964A2 (en) | 2016-09-28 | 2019-08-07 | Bavarian Nordic A/S | Compositions and methods for enhancing the stability of transgenes in poxviruses |
| EP3522920A2 (en) | 2016-10-10 | 2019-08-14 | Transgene SA | Immunotherapeutic product and mdsc modulator combination therapy |
| WO2018091680A1 (en) | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
| JP7110203B2 (ja) | 2016-12-28 | 2022-08-01 | トランジェーヌ | 腫瘍溶解性ウイルスおよび治療用分子 |
| CN110770345A (zh) | 2017-04-14 | 2020-02-07 | 托尔奈公司 | 免疫调节多核苷酸、抗体缀合物及其使用方法 |
| EP3624845A1 (en) | 2017-05-15 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| WO2018210804A1 (en) | 2017-05-15 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| WO2019020543A1 (en) | 2017-07-28 | 2019-01-31 | Transgene Sa | ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS |
| KR102754876B1 (ko) | 2017-08-24 | 2025-01-13 | 버베리안 노딕 에이/에스 | 재조합 mva 및 항체의 정맥내 투여에 의한 암 치료를 위한 병용 요법 |
| CN112512560A (zh) | 2018-03-07 | 2021-03-16 | 特兰斯吉恩股份有限公司 | 副痘病毒属载体 |
| WO2020011754A1 (en) | 2018-07-09 | 2020-01-16 | Transgene | Chimeric vaccinia viruses |
| WO2020049151A1 (en) | 2018-09-06 | 2020-03-12 | Bavarian Nordic A/S | Storage improved poxvirus compositions |
| US20220233607A1 (en) | 2019-05-29 | 2022-07-28 | Université De Tours | Toxoplasma platform for treating cancer |
| CA3169523A1 (en) | 2020-02-28 | 2021-09-02 | Jaume Pons | Transglutaminase-mediated conjugation |
| JP7712284B2 (ja) | 2020-03-12 | 2025-07-23 | バヴァリアン・ノルディック・アクティーゼルスカブ | ポックスウイルスの安定性を改善する組成物 |
| TW202413636A (zh) | 2022-08-18 | 2024-04-01 | 法商傳斯堅公司 | 嵌合痘病毒 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US5833975A (en) * | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
| US5174993A (en) * | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
| DK354487A (da) * | 1986-07-11 | 1988-01-12 | Noboru Yanaihara | Oncogen-relaterede peptider |
| US5266313A (en) * | 1987-02-03 | 1993-11-30 | The United States Of America As Represented By The Department Of Health And Human Services | Raccoon poxvirus as a gene expression and vaccine vector for genes of rabies virus and other organisms |
| DE10399032I1 (de) | 1987-08-28 | 2004-01-29 | Health Research Inc | Rekombinante Viren. |
| CA1340203C (en) | 1987-09-16 | 1998-12-15 | Noboru Yanagida | Recombinant apivoxvirus |
| US5093258A (en) | 1988-08-26 | 1992-03-03 | Therion Biologics Corporation | Recombinant fowlpox virus and recombination vector |
| WO1991019803A1 (en) | 1990-06-19 | 1991-12-26 | Applied Biotechnology, Incorporated | Self assembled, defective, nonself-propagating viral particles |
| ATE248924T1 (de) * | 1991-05-06 | 2003-09-15 | Us Gov Health & Human Serv | Karcinoembryonale antigen expremierende rekombinante viren und methoden ihrer anwendung |
| US5445953A (en) | 1991-08-26 | 1995-08-29 | Immuno Aktiengesellschaft | Direct molecular cloning of a modified poxvirus genome |
| US5382425A (en) * | 1992-01-13 | 1995-01-17 | Syntro Corporation | Recombinant swinepox virus |
| US5374149A (en) | 1993-01-13 | 1994-12-20 | Computower Technologies, Corp. | Vertical storage conveyor with symmetrical motor drive system |
| WO1996011279A2 (en) * | 1994-10-03 | 1996-04-18 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system |
| EP1016418B1 (en) * | 1994-10-03 | 2009-12-30 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Host cell comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule |
| US6001349A (en) * | 1995-02-22 | 1999-12-14 | Therion Biologics Corporation | Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof |
| US6165460A (en) * | 1995-07-10 | 2000-12-26 | Therion Biologics Corporation | Generation of immune responses to prostate-specific antigen (PSA) |
-
1997
- 1997-07-15 WO PCT/US1997/012203 patent/WO1998004727A1/en not_active Ceased
- 1997-07-15 JP JP50884498A patent/JP4475683B2/ja not_active Expired - Lifetime
- 1997-07-15 EP EP09010415A patent/EP2112225A1/en not_active Ceased
- 1997-07-15 AU AU37268/97A patent/AU731860B2/en not_active Ceased
- 1997-07-15 EP EP97934142A patent/EP0954593A1/en not_active Withdrawn
- 1997-07-15 CA CA002261989A patent/CA2261989C/en not_active Expired - Fee Related
-
2002
- 2002-07-17 US US10/197,127 patent/US7410644B2/en not_active Expired - Fee Related
-
2009
- 2009-07-22 JP JP2009171254A patent/JP2009278997A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP0954593A1 (en) | 1999-11-10 |
| WO1998004727A1 (en) | 1998-02-05 |
| JP2009278997A (ja) | 2009-12-03 |
| AU731860B2 (en) | 2001-04-05 |
| US7410644B2 (en) | 2008-08-12 |
| AU3726897A (en) | 1998-02-20 |
| JP4475683B2 (ja) | 2010-06-09 |
| EP2112225A1 (en) | 2009-10-28 |
| US20030003079A1 (en) | 2003-01-02 |
| JP2000516459A (ja) | 2000-12-12 |
| CA2261989A1 (en) | 1998-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2261989C (en) | Recombinant pox virus for immunization against tumor-associated antigens | |
| US7118738B2 (en) | Recombinant pox virus for immunization against MUC1 tumor-associated antigen | |
| AU774076B2 (en) | A recombinant vector expressing multiple costimulatory molecules and uses thereof | |
| US6969609B1 (en) | Recombinant vector expressing multiple costimulatory molecules and uses thereof | |
| AU2004289340B2 (en) | System for treating and preventing breast cancer | |
| AU718945B2 (en) | Recombinant pox virus for immunization against tumor-associated antigens | |
| CA2252406A1 (en) | Heterologous boosting immunizations | |
| US20050100558A1 (en) | Heterologous boosting immunizations | |
| AU767562B2 (en) | Recombinant pox virus for immunization against tumor-associated antigens | |
| AU2003266471A1 (en) | Recombinant pox virus for immunization against tumor-associated antigens | |
| EP1865065A1 (en) | A recombinant vector expressing multiple costimulatory molecules and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20170717 |